LinusBio will develop a technology platform that builds on breakthroughs in exposome sequencing by environmental medicine and public health specialists Drs. Manish Arora, Christine Austin, and Paul Curtin, co-founders of the company. The trio developed a method for sequencing the exposome and biological responses at a molecular level using an environmental biodynamics platform.

The spinoff's pipeline includes precision exposome medicine biomarkers across disease domains for which historically no molecular endpoints have been available in clinical trials, including autism spectrum disorder, amyotrophic lateral sclerosis, inflammatory bowel disease, renal disease, and oncology, the company said. These are diseases for which genomic sequencing alone cannot sufficiently characterize underlying biological disease pathways.

Subject to regulatory approvals, LinusBio intends to launch its first product, StrandDx-ASD, a molecular biomarker for autism spectrum disorder that can be applied at birth, LinusBio said.

Researchers dig into how myeloid cells contribute to killing cancer
WASHINGTON, DC - Dr. Miriam Merad, PhD, director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai is working on characterizing...

BridgeBio developing therapies with Columbia University, Mount Sinai
BridgeBio Pharma announced it is collaborating with Columbia University and Mount Sinai Health System to develop potential therapies to treat individuals...

Synchron lands NIH grant for brain computer interface trial
Synchron has been awarded a $10 million grant by the U.S. National Institutes of Health (NIH) to study its Synchron motor neuroprosthesis in a new clinical...